Alcidion (ASX: ALC) H1 FY 2024 Results
Alcidion (ASX: ALC) would probably be worth more to an acquirer, than as a public company.
Alcidion Group Ltd (ASX: ALC) is a medical software company specialising in patient flow software for hospitals. Basically, Alcidion’s Miya platform makes it easier for nurses to manage beds in wards, and ensures that the appropriate medico has assessed test results, and taken appropriate action. Alcidion can be seen as an important software partner for public healthcare systems such as Australia’s Medicare, and the United Kingdom’s NHS.
Alcidion (ASX: ALC) would probably be worth more to an acquirer, than as a public company.
Yet another disappointing quarterly from Alcidion (ASX: ALC), as much needed contract wins fail to materialise.
Here are some of the small-cap Annual General Meetings coming up this month.
Alcidion (ASX: ALC) is raising capital due delays in NHS procurement.
Alcidion’s CEO Kate Quirke says “we have a very long runway ahead of us” and “at this stage I am confident.”
Alcidion’s cashflow is heading in the right direction but still no word on when to expect statutory profits.
NHS strikes are taking a toll on Alcidion’s sales cycle.
A couple of late payments (now received) contributed to disappointing cashflow for Alcidion, in Q2 FY 2023.
Alcidion is an unprofitable healthcare software stock, and Duratec is a low margin contractor. But both companies are winning new contracts.
PWR Holdings results, Objective
results, Alcidion results, Lovisa results and Laserbond results were all strong in FY 2022.
These two med-tech stocks are still fairly high risk, but they are approaching the profitability inflection point, and have long term tailwinds supporting the businesses.
The Alcidion (ASX: ALC) is flat today as the company reports weaker operating cash flow due to acquisition expenses.
The drop in recurring revenue means that the company is lower quality than I had previously believed.
Alcidion (ASX:ALC) is bolstering its product offering with its acquisition of Silverlink Software. What does it mean for shareholders?
The Alcidion share price is up around 10% after it confirmed its largest ever contract win, worth at least $23 million.
Some stocks have high multiples and higher growth rates, others have lower multiples and lower growth rates. Here’s how I decided which one to choose.
The Alcidion share price gained as much as 16% today after it released its quarterly results to June 2021.
Less than a year after we published “The Case For Alcidion” the stock is up 160%, so it’s time to revisit the thesis.
Alcidion shares are trading at near to all time highs, the business is growing recurring revenue, and it’s winning new contracts in the UK.
The Alcidion share price, Whispir share price, and Secos share price all climbed after they reported quarterly results. Here’s why…